In August 2013, the Gorlin Syndrome Group conducted a media outreach activity to highlight its recent survey.
New oral treatment Erivedge (vismodegib) now authorised for UK use.
Roche announce that the European Commission has granted conditional approval to Erivedge.
The New England Journal of Medicine yesterday released a report on the "Efficacy and Safety of Vismodegib in advanced Basal Cell Carcinoma".
If you are considering Photodynamic Therapy as a treatment for basal cell carcinomas you may be interested in reading all about it.
Cancer patients urged to apply for free prescriptions from 25th January 2009. People being treated for cancer will be eligible for free prescriptions from 1st April 2009 and can apply for free prescriptions from today.
Originally produced by Professor P. A. Farndon, Clinical Geneticist, Jim Costello (deceased) and Margaret Costello. We are reliant on a team of medical advisors for the clinical content of the website. We are grateful for their continuing support.
Gorlin Syndrome Group is Registered Charity in the UK - No 1096361